Cheng-Jung Lai

Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-<i>N</i>-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer

Xiong Cai, Hai-Xiao Zhai, Jing Wang et al. · Journal of Medicinal Chemistry · 2010 · 258 citations · Full text

Chemoprevention Strategy, Pharmacotherapy, Pharmaceutical Chemistry +18

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

Changgeng Qian, Cheng-Jung Lai, Rudi Bao et al. · Clinical Cancer Research · 2012 · 236 citations

CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity

Cheng-Jung Lai, Rudi Bao, Xu Tao et al. · Cancer Research · 2010 · 211 citations · Full text

Dermatology, Cancer Biology, Tumor Biology +16

Distinct expression and shared activities of members of the <i>hedgehog</i> gene family of <i>Xenopus laevis</i>

Stephen C. Ekker, L. Lynn McGrew, Cheng-Jung Lai et al. · Development · 1995 · 202 citations

CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy

Rudi Bao, Cheng-Jung Lai, Hui Qu et al. · Clinical Cancer Research · 2009 · 111 citations · Full text